On March 10, 2022 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, reported that it will present new studies on its TGF- β program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana (Press release, Oncotelic, MAR 10, 2022, View Source [SID1234609913]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will demonstrate a close relationship between TGF-β expression and immune evasion by cancer and SARS-CoV-2. Details of the presentation are as follows:
Presentation Title: Mutational analysis of ORF-8 of SARS-CoV-2 – a window to immunotherapy. Session Title: Cancer Genomics. Session Category: Molecular and Cellular Biology/Genetics. Abstract Number: 2937
The AACR (Free AACR Whitepaper) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
In August 2021, the Company and GMP entered into a term sheet, including certain binding terms, to form a JV to develop Oncotelic’s drug portfolio and build out a manufacturing facility. Also, the Company had announced, and subsequently reported in our Quarterly Report on form 10-Q filed with the SEC on August 17, 2021, the intent to take the JV into an initial public offering ("IPO") at a future date. On February 14th, the Company and GMP agreed to extend the standstill terms of the term sheet until March 31, 2022 to permit the completion of the transaction.
"Oncotelic’s goal is to create novel immune based therapies for oncology and virology. Development of drugs is an expensive endeavor, and the JV is intended to ensure sufficient financial resources to get the Company’s portfolio to marketing approval and beyond." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.